A French national survey on infiltrating breast cancer: Analysis of clinico-pathological features and treatment modalities in 1159 patients

Breast Cancer Research and Treatment

Volumn 95, Issue 1, 2006, Pages 55-64

  Cutuli, Bruno ^a   Cottu, Paul Henri ^b   Guastalla, Jean Paul ^c   Mechin, Hubert ^d   Costa, Anne ^d   Jourdan, Rosemary ^e  

^a Polyclinique de Courlancy ^*  (France)

^b GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^c CENTRE LÉON BÉRARD   (France)

^d MAPI GROUP   (Netherlands)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Hormone receptors; Hormone replacement therapy; Infiltrating breast cancer; Nodal involvement; Radiotherapy; Survey; Treatment

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL PRACTICE; FEMALE; FRANCE; HEALTH SURVEY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PATIENT; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRANCE; HEALTH SURVEYS; HUMANS; MASTECTOMY; MENOPAUSE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 32444443634     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9034-6     Document Type: Article

References (77)

1. Menegoz F, Black RJ, Arveux P, Magne V, Ferlay J, Buemi A, Carli PM, Chapelain G, Faivre J, Gignoux M, Grosclaude P, Mace-Lesec'H J, Reveroy N, Schaffer P: Cancer incidence and mortality in France 1975-95. Eur J Cancer Prev 6: 442-466, 1997
2. Hill C, Doyon F: Fréquence des cancers en France. Bull Cancer 90: 207-213, 2003
3. Marty M, Rossignol C, Serruys G, Petrissans JL, Baillet F, Netter-Pinon G, Romieux G, Saez S: Le cancer du sein au moment du diagnostic. Etude nationale de la canam: analyse de 3007 cas. Presse Med 21: 1017-1021, 1992
4. Grosclaude P, Colonna M, Hedelin G, Tretarre B, Arveux P, Lesec'h JM, Raverdy N, Sauvage-Machelard M: Survival of women with breast cancer in France: variation with age, stage and treatment. Breast Cancer Res Treat 70: 137-143, 2001
5. Chaplain G, Cuisenier J, Le Dorze L, Pansiot F, Bastien H: Le cancer du sein dans le département de la Côte d'Or (1982-1987). Registre bourguignon de la pathologie gynécologique. Bull Cancer 77: 5-14, 1990
6. Aptel I, Grosclaude P, Duchene Y, Sauvage M: Stade des cancers du sein dans une région sans dépistage systématique. Bulletin Epidémiologique Hebdomadaire 22: 91-93, 2000
7. Abadie C, Aminot I, Dupuy E, Degre A: Cancer du sein I. Situation épidémiologique en Aquitaine en 1999. Rev Med Ass Mal 33: 173-181, 2002
8. Abadie C, Aminot I, Dupuy E, Degre A: Cancer du sein II. Evaluation des pratiques diagnostiques et thérapeutiques en Aquitaine en 1999. Rev Med Ass Mal 33: 264-276, 2002
9. Bland KI, Menck HR, Scott-Conner CE, Morrow M, Winchester DJ, Winchester DP: The national cancer database 10-year survey of breast carcinoma treatment at hospitals in the united states. Cancer 83: 1262-1273, 1998
10. Harvey JM, Sterrett GF, Parsons RW, Fitzgerald CJ, Jamrozik K, Dewar JM, Byrne MJ, Ingram DM, Sheiner HM: Breast cancer in Western Australia in 1989: IV Summary of histopathological assessment in 655 cases. Pathology 27: 12-17, 1995
11. Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP: Hormone receptors status of breast tumors in black, hispanic and non-hispanic white women. An analysis of 13.239 cases. Cancer 77: 1465-1471, 1996
12. Olivotto IA, Jackson JS, Mates D, Andersen S, Davidson W, Bryce CJ, Ragaz J: Prediction of axillary lymph node involvement of women with invasive breast carcinoma. A multivariate analysis. Cancer 83: 948-955, 1998
13. Chaplain G, Coudert B, Milan C, Altwegg T, Esteve J: Changing practice in systemic breast cancer adjuvant treatment in a well-defined French population. Bull Cancer 86: 855-860, 1999
14. Gann PH, Colilla SA, Gapstur SM, Winchester DJ, Winchester DP: Factors associated with axillary lymph node metastatic from breast carcinoma descriptive and prediction analysis. Cancer 86: 1511-1519, 1999
15. Yiangou C, Shousha S, Sinnett HD: Primary tumour characteristics and axillary lymph node status in breast cancer. Br J Cancer 80: 1974-1978, 1999
16. Huang W, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PC: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151: 703-714, 2000
17. Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. J Clin Oncol 19: 3103-3110, 2001
18. Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21: 28-34, 2003
19. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3 2000. J Natl Cancer Inst 93: 979-989, 2001
20. Ashba J, Traish AM: Estrogen and progesterone receptor concentrations and prevalence of tumor hormonal phenotypes in older breast cancer patients. Cancer Detect Prevent 23: 238-244, 1999
21. Jordan VC: The ups and downs of the estrogen receptors. J Clin Oncol 21: 3-4, 2003
22. Romain S, Bidron CL, Martin PM, Magdalenat H: Steroid receptor distribution in 47892 breast cancers. A collaborative study of 7 European laboratories. Eur J Cancer 31a: 411-417, 1995
23. Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelenat H, Sastre-Garau X: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37: 536-545, 2000
24. Pujol P, Hilsenbeck SG, Chamness GC, Elledge RM: Rising levels of estrogen receptors in breast cancer over 2 decades. Cancer 74: 1601-1606, 1994
25. Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10: 431-437, 1999
26. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37-45, 2001
27. Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R: Assessment of HER2 status in breast cancer: why, when and how?. Eur J Cancer 36: 170-176, 2000
28. Estevez LG, Seidman AD: Her 2 - positive breast cancer. Incidence, prognosis and treatment options. Am J Cancer 2: 169-179, 2003
29. Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlbock M, Jakesz R: Do we need HER-2/neu testing for all patients with primary breast carcinoma?. Cancer 98: 2547-2553, 2003
30. Bonnier P, Sakr R, Bessenay F, Lejeune C, Charpin C, Martin PM, Piana L: Effets des traitements hormonaux substitutifs de la ménopause sur les facteurs pronostiques des cancers du sein. Gynecol Obstet Fertil 28: 745-753, 2000
31. Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA, Hole D: Effect of hormone replacement therapy on the pathological stage of breast cancer population based, cross sectional study. BMJ 320: 348-349, 2000
32. Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G, Veronesi U: Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9: 266-271, 2002
33. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Camey PA: Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21: 4314-4321, 2003
34. Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Moller S, Rank F, Ottesen B, Lynge E: Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 91: 644-650, 2004
35. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, Mc Tiernan A: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA 289: 3243-3253, 2003
36. Le Mg, Plu-Bureau G: THS et cancer du sein: le verdict est-il définitif?. Ref Gynecol Obst 10: 3-7, 2003
37. Fourquet A, Cutuli B, Luporsi E, Mauriac L, Garbay JR, Giard S, Spyratos F, Sigal-Zafrani B, Dilhuydy JM, Acharian V, Balu-Maestro C, Blanc-Vincent MP, Cohen-Solal C, De Lafontan B, Dilhuydy MH, Duquesne B, Gilles R, Lesur A, Shen N, Cany L, Dagousset I, Gaspard MH, Hoarau H, Hubert A, Monira MH, Perrie N, Romieu G: Standards, options et recommandations 2001 pour la radiothérapie des patientes atteintes d'un cancer du sein infiltrant non métastatique, mise à jour. Cancer-Radiother 6: 238-258, 2002
38. Mauriac L, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Sigal-Zafrani B, Dilhuydy JM, Acharian V, Balu-Maestro C, Blanc-Vincent MP, Cohen-Solal C, De Lafontan B, Dilhuydy MH, Duquesne B, Gilles R, Lesur A, Shen N, Cany L, Dagousset I, Gaspard MH, Hoarau H, Hubert A, Monira MH, Perrie N, Romieu G: Summary version of the Standards, Options and Recommendations for nonmetastactic breast cancer (update January 2001). Br J Cancer 89(suppl 1): s17-s31, 2003
39. Du X, Freeman JL, Freeman DH, Syblik DA, Goodwill JS: Temporal and regional variation in the use of breast-conserving surgery and radiotherapy for older women with early stage breast cancer from 1983 to 1995. J Gerontol A Biol Sci Med 54: M474-478, 1999
40. Hebert-Croteau N, Brisson J, Latreille J, Blanchette C, Deschenes L: Compliance with consensus recommendation for the treatment of early stage breast carcinoma in elderly women. Cancer 85: 1104-1113, 1999
41. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, Harris JR, O'Malley F, Schnitt SJ, Singletary SE, Winchester DP: Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin 52: 277-300, 2002
42. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21: 3580-3587, 2003
43. White J, Morrow M, Moughan J, Owen J, Pajak T, DesHarnais S, Winchester DP, Wilson JF: American College of Surgeons Commission on Cancer; American College of Radiology Patterns of Care Study: Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 97: 893-904, 2003
44. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24 740 breast cancer cases. Cancer 63: 181-187, 1989
45. Sasco AJ, Fontaniere B, Charbaut-Lagarde MO, Kliebsch U, Hamandjian P, Cornu-Lugrin AE, Schnebelen JP, Sciortino V, Fabry J: A systematic survey of breast cancer incidence in the department of Rhône, France. Eur J Cancer 27: 1696-1701, 1991
46. Barchielli A, Balzi D: Age at diagnosis extent of disease and breast cancer survival: a population-based study in Florence, Italy. Tumori 86: 119-123, 2000
47. Blichert-Toft M: Axillary surgery in breast cancer management background, incidence and extent of nodal spread, extent of surgery and accurate axillary staging, surgical procedures. Acta Oncologica 39: 269-275, 2000
48. Silverstein MJ, Skinner KA, Lomis TJ: Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 25: 767-772, 2001
49. Kirucuta CI, Tausch J: A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 69: 2496-2501, 1992
50. Martin C, Cutuli B, Velten M: Predictive model of axillary lymph node involvement in women with small invasive breast carcinoma. Cancer 94: 314-322, 2002
51. Krag DN, Single RM: Breast cancer survival according to number of nodes removed. Ann Surg Oncol 10: 1152-1159, 2003
52. Kjaergard J, Blichert-Toft M, Andersen JA, Rank F: Probability false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg 72: 365-367, 1985
53. Schwartz GF, Giuliano AE, Veronesi U: Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22 2001, Philadelphia, Pennsylvania. Cancer 94: 2542-2551, 2002
54. Wong SL, Abell TH, Chad C, Edwards MJ, McMasters KM: Optimal use of sentinel lymph node biopsy versus axillary lymph node detection in patients with breast carcinoma A decision analysis. Cancer 95: 478-487, 2002
55. Rutgers EJ: Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more?. Eur J Cancer 40: 182-186, 2004
56. Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC: The natural history of breast carcinoma. What have we learned from screening?. Cancer 86: 449-462, 1999
57. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349: 546-553, 2003
58. Cutuli B: The impact of loco-regional radiotherapy on the survival of breast cancer. Pro. Eur J Cancer 36: 1895-2000, 2000
59. Early Breast Cancer Trialist's Collaborative Group Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355: 1757-1770, 2000
60. Van De Steene J, Soete G, Strome G: Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol 55: 263-272, 2000
61. Whelan T, Julian J, Wright J, Jadad A, Levine M: Does locoregional radiation therapy improve survival in breast cancer ? A meta analysis. J Clin Oncol 18: 1220-1229, 2000
62. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M: EORTC Radiotherapy and Breast Groups: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345: 1378-1387, 2001
63. Vinh-Hung V, Burzykowski T, Van De Steene J, Storme G, Soete G: Post-surgery radiation in early breast cancer: survival analysis of registry date. Radiother Oncol 64: 281-290, 2002
64. Poortmans P, Bartelink H, Horiot JC: The influence of the boost technique on local control in breast conserving treatment in the EORTC "boost versus no boost" randomized trial. Radiother Oncol 72: 25-33, 2004
65. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R, Roter D: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer November 1-3 2000. J Natl Cancer Inst 93:979-989, 2001
66. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, Hortobagyi G, Buzdar AU, Theriault R, Singletary SE, Mc Neese M: Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18: 2817-2827, 2000
67. Sartor CI: Post mastectomy radiotherapy in women with breast cancer metastatic to one to three axillary lymph nodes. Curr Oncol Reports 2: 497-505, 2001
68. Kurtz J: The curative role of radiotherapy in the treatment of operable breast cancer. Eur J Cancer 38: 1961-1974, 2002
69. Elkuizen PH, Hermans J, Leer JW, Van De Vijver MJ: Isolated late local recurrence with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastases. Int J Radiat Oncol Biol Phys 50: 387-396, 2001
70. Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, Dirschedl P, Holzel D: Determinants and prognoses of locoregional and distant progression in breast cancer. In t J Radiat Oncol Biol Phys 55: 1186-1195, 2003
71. Kuske RR: Adjuvant chest wall and nodal irradiation: maximize cure, minimize late cardiac toxicity. J Clin Oncol 16: 2579-2582, 1998
72. Hojris I, Overgaard M, Christensen J, Overgaard J: Morbidity and mortality of ischaemic heart disease in high risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Lancet 354: 1425-1430, 1999
73. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 19: 3817-3827, 2001
74. Cardoso F, Piccart MJ: The best use of chemotherapy in the adjuvant setting. The Breast 12: 522-528, 2003
75. Espie M, Cuvier C, Giacchetti S: Anthracyclines et cancer du sein. Oncologie 5: s120-s124, 2003
76. French Adjuvant Study Group Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5 years follow-up results of French adjuvant study group 05 randomized trial. J Clin Oncol 19: 599-601, 2000
77. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialist's Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005